Atlas Trials

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Clinical trial NCT05269667 · TERMINATED

Trial details

NCT number
NCT05269667
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Neuromyelitis Optica Spectrum DisorderNMOSD
Start date
2022-08-02
Primary completion
2023-10-26
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.